Accession Number:

ADA612221

Title:

Novel Small-Molecule Antibacterial Agents

Descriptive Note:

Final rept. 15 Apr 2009-14 May 2014

Corporate Author:

MAYO CLINIC ROCHESTER MN

Personal Author(s):

Report Date:

2014-07-01

Pagination or Media Count:

6.0

Abstract:

The specific aim of this proposal is to develop improved small-molecule botulinum neurotoxin serotype A endopeptidase BoNTAe inhibitors with Ki values of 100 nM. We have developed BoNTAe inhibitors MHC and HAB see US Patent 8,404,728 B2 that showed significant 6-hour-post-exposure protection of mice against 5 LD50 BoNTA. HAB also showed significant 4-hour-post-exposure protection of zebrafish against 5 LD50 BoNTA. Our kinetics and affinity analyses using the surface plasmon resonance technique showed that the Ki value of our BoNTAe inhibitor AHP see US Patent 8,404,728 B2 is 71 or - 26 nM 2 independent experiments with chi square values of 0.393 and 0.396. In addition, we have developed a generic approach to cysteine-targeting irreversible inhibitors of pathogenic enzymes Adv. Insect Physiol. 46, 435-494, 2014 that enables conversion of our reversible BoNTAe inhibitors to irreversible inhibitors that target Cys164 in the BoNTAe active site to effectively counteract BoNTA that has an unusually long in vivo half life of 31 days.

Subject Categories:

  • Toxicology
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE